{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T17:56:11Z","timestamp":1771264571580,"version":"3.50.1"},"reference-count":106,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2020,5,6]],"date-time":"2020-05-06T00:00:00Z","timestamp":1588723200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004895","name":"European Social Fund","doi-asserted-by":"publisher","award":["PON I&C 2014-2020 \u2013 F\/050383\/01-03\/X32"],"award-info":[{"award-number":["PON I&C 2014-2020 \u2013 F\/050383\/01-03\/X32"]}],"id":[{"id":"10.13039\/501100004895","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Simultaneous care represents the ideal integration between early supportive and palliative care in cancer patients under active antineoplastic treatment. Cancer patients require a composite clinical, social and psychological management that can be effective only if care continuity from hospital to home is guaranteed and if such a care takes place early in the course of the disease, combining standard oncology care and palliative care. In these settings, venous thromboembolism (VTE) represents a difficult medical challenge, for the requirement of acute treatments and for the strong impact on anticancer therapies that might be delayed or, even, totally discontinued. Moreover, cancer patients not only display high rates of VTE occurrence\/recurrence but are also more prone to bleeding and this forces clinicians to optimize treatment strategies, balancing between hemorrhages and thrombus formation. VTE prevention is, therefore, regarded as a double-edged sword. Indeed, while on one hand the appropriate use of antithrombotic agents can reduce VTE occurrence, on the other it significantly increases the bleeding risk, especially in the frail patients who present with multiple co-morbidities and poly-therapy that can interact with anticoagulant drugs. For these reasons, thromboprophylaxis should start while active cancer treatment is ongoing, according to a simultaneous care model in a patient-centered perspective.<\/jats:p>","DOI":"10.3390\/cancers12051167","type":"journal-article","created":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T04:46:07Z","timestamp":1588826767000},"page":"1167","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Venous Thromboembolism in Cancer Patients on Simultaneous and Palliative Care"],"prefix":"10.3390","volume":"12","author":[{"given":"Silvia","family":"Riondino","sequence":"first","affiliation":[{"name":"Department of Systems Medicine, Medical Oncology, University of Rome, Tor Vergata, 00133 Rome, Italy"},{"name":"Department of Human Sciences and Quality of Life Promotion, San Raffaele Roma Open University, 00166 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9877-8712","authenticated-orcid":false,"given":"Patrizia","family":"Ferroni","sequence":"additional","affiliation":[{"name":"Department of Human Sciences and Quality of Life Promotion, San Raffaele Roma Open University, 00166 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Girolamo","family":"Del Monte","sequence":"additional","affiliation":[{"name":"Department of Palliative Care, San Raffaele Cassino, Clinical Center, 03043 Cassino, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Formica","sequence":"additional","affiliation":[{"name":"Department of Systems Medicine, Medical Oncology, University of Rome, Tor Vergata, 00133 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fiorella","family":"Guadagni","sequence":"additional","affiliation":[{"name":"Department of Human Sciences and Quality of Life Promotion, San Raffaele Roma Open University, 00166 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Roselli","sequence":"additional","affiliation":[{"name":"Department of Systems Medicine, Medical Oncology, University of Rome, Tor Vergata, 00133 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,5,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.7150\/jca.14634","article-title":"Early Integration of Palliative Care in Oncology Practice: Results of the Italian Association of Medical Oncology (AIOM) Survey","volume":"7","author":"Zagonel","year":"2016","journal-title":"J. Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1093\/annonc\/mdx757","article-title":"European Society for Medical Oncology (ESMO) position paper on supportive and palliative care","volume":"29","author":"Jordan","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1056\/NEJMoa1000678","article-title":"Early palliative care for patients with metastatic non-small-cell lung cancer","volume":"363","author":"Temel","year":"2010","journal-title":"New Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1001\/jama.2009.1198","article-title":"Effects of a palliative care intervention on clinical outcomes in patients with advanced cancer: The project ENABLE II randomized controlled trial","volume":"302","author":"Bakitas","year":"2009","journal-title":"JAMA"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"j2925","DOI":"10.1136\/bmj.j2925","article-title":"Effect of specialist palliative care services on quality of life in adults with advanced incurable illness in hospital, hospice or community settings: Systematic review and meta-analysis","volume":"357","author":"Gaertner","year":"2017","journal-title":"BMJ"},{"key":"ref_6","unstructured":"WHO (2020, May 03). Definition of Palliative Care. Available online: https:\/\/www.who.int\/cancer\/palliative\/definition\/en\/."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1093\/annonc\/mdg379","article-title":"ESMO Taskforce on Supportive and Palliative Care. ESMO takes a stand on supportive and palliative care","volume":"14","author":"Cherny","year":"2003","journal-title":"Ann. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1093\/annonc\/mdw654","article-title":"Use of chemotherapy near the end of life: What factors matter?","volume":"28","author":"Rochigneux","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1200\/JCO.2010.33.1744","article-title":"American Society of Clinical Oncology. American Society of Clinical Oncology statement: Toward individualized care for patients with advanced cancer","volume":"29","author":"Peppercorn","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.6004\/jnccn.2012.0132","article-title":"NCCN (National Comprehensive Cancer Network). Palliative care","volume":"10","author":"Levy","year":"2012","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e588","DOI":"10.1016\/S1470-2045(18)30415-7","article-title":"Integration of oncology and palliative care: A Lancet Oncology Commission","volume":"19","author":"Kaasa","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/S1470-2045(16)30573-3","article-title":"Defining cancer survivors, their needs and perspectives on survivorship health care in the USA","volume":"18","author":"Mayer","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1200\/JCO.2011.38.5161","article-title":"American Society of Clinical Oncology provisional clinical opinion: The integration of palliative care into standard oncology care","volume":"30","author":"Smith","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s00520-008-0559-1","article-title":"The Medical Care Continuity (MCC) project. A pilot study of video-assisted home care within the eTEN European Community program. The Italian experience","volume":"17","author":"Formica","year":"2009","journal-title":"Support. Care Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1097\/NJH.0b013e3181bd03b7","article-title":"A new model of palliative care for oncology patients with advanced disease","volume":"11","author":"Mazanec","year":"2009","journal-title":"J. Hosp. Palliat. Nurs."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1200\/JCO.2008.20.1558","article-title":"Palliative cancer care a decade later: Accomplishments, the need, next steps\u2014From the American Society of Clinical Oncology","volume":"27","author":"Ferris","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_17","first-page":"223","article-title":"Early outpatient referral to palliative care services improves end-of-life care","volume":"64","author":"Barton","year":"2014","journal-title":"J. Clin."},{"key":"ref_18","unstructured":"Institute of Medicine (US) Committee on Quality of Health Care in America (2001). Crossing the Quality Chasm: A New Health System for the 21st Century, National Academies Press (US)."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1177\/0269216308098477","article-title":"Reflecting the scope and work of palliative care teams today: An action research project to modernise a national minimum data set","volume":"23","author":"Jack","year":"2009","journal-title":"Palliat. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.hoc.2012.02.010","article-title":"Venous thromboembolism overview","volume":"26","author":"Battinelli","year":"2012","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1200\/JCO.2013.49.1118","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology Clinical Practice Guideline Update","volume":"31","author":"Lyman","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1586\/14737140.4.2.303","article-title":"Venous thromboembolism and malignancy","volume":"4","author":"Gao","year":"2004","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3390\/medicina44030022","article-title":"Venous thromboembolism and prophylaxis in cancer patients","volume":"44","author":"Paskauskas","year":"2008","journal-title":"Medicina"},{"key":"ref_24","first-page":"437","article-title":"Cancer and venous thromboembolism: An overview","volume":"84","author":"Prandoni","year":"1999","journal-title":"Haematologica"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1002\/ijc.28104","article-title":"Impact of chemotherapy on activated protein C-dependent thrombin generation\u2014Association with VTE occurrence","volume":"133","author":"Roselli","year":"2013","journal-title":"Int. J. Cancer"},{"key":"ref_26","first-page":"CD003407","article-title":"Erythropoietin or darbepoetin for patients with cancer","volume":"3","author":"Bohlius","year":"2006","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"102","DOI":"10.2174\/157016110790226660","article-title":"Thromboembolic events in patients treated with anti-angiogenic drugs","volume":"8","author":"Ferroni","year":"2010","journal-title":"Curr. Vasc. Pharmacol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/jamainternmed.2013.122","article-title":"Use of glucocorticoids and risk of venous thromboembolism: A nationwide population-based case-control study","volume":"173","author":"Johannesdottir","year":"2013","journal-title":"JAMA Intern. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1001\/archinte.160.22.3431","article-title":"Clinical risk factors and timing of recurrent venous thromboembolism during the initial 3 months of anticoagulant therapy","volume":"160","author":"Douketis","year":"2000","journal-title":"Arch. Intern. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1160\/TH10-05-0277","article-title":"Incidental venous thromboembolism in ambulatory cancer patients receiving chemotherapy","volume":"104","author":"Ferrante","year":"2010","journal-title":"Thromb. Haemost."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.3324\/haematol.2012.073338","article-title":"Regional lymph node metastases are a strong risk factor for venous thromboembolism: Results from the Vienna Cancer and Thrombosis Study","volume":"98","author":"Dickmann","year":"2013","journal-title":"Haematologica"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3747\/co.22.2586","article-title":"Canadian consensus recommendations on the management of venous thromboembolism in patients with cancer. Part 1: Prophylaxis","volume":"22","author":"Easaw","year":"2015","journal-title":"Curr. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.1002\/cncr.26597","article-title":"Risk assessment models for cancer-associated venous thromboembolism","volume":"118","author":"Dutia","year":"2012","journal-title":"Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1093\/annonc\/mdj068","article-title":"Risk factors for venous thromboembolic events in cancer patients","volume":"17","author":"Kroger","year":"2006","journal-title":"Ann. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1182\/blood-2002-01-0108","article-title":"Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis","volume":"100","author":"Prandoni","year":"2002","journal-title":"Blood"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.2174\/0929867323666161018144505","article-title":"Gender differences in cancer-associated venous thromboembolism","volume":"24","author":"Riondino","year":"2017","journal-title":"Curr. Med. Chem."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3770","DOI":"10.1182\/bloodadvances.2019000369","article-title":"Managing the competing risks of thrombosis, bleeding and anticoagulation in patients with malignancy","volume":"3","author":"Connors","year":"2019","journal-title":"Blood. Adv."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11239-015-1311-6","article-title":"The epidemiology of venous thromboembolism","volume":"41","author":"Heit","year":"2016","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.jamda.2013.02.003","article-title":"Incidence of venous thromboembolism in nursing home residents","volume":"14","author":"Reardon","year":"2013","journal-title":"J. Am. Med. Dir. Assoc."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1046\/j.1525-1497.2003.21133.x","article-title":"Incidence of venous thromboembolic events among nursing home residents","volume":"18","author":"Gomes","year":"2003","journal-title":"J. Gen. Intern. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0885-3924(00)00115-9","article-title":"Diagnosis of venous thromboembolism in cancer patients receiving palliative care","volume":"19","author":"Merminod","year":"2000","journal-title":"J. Pain Symptom Manag."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1177\/0269216308098803","article-title":"Venous thromboembolism in patients with advanced cancer under palliative care: Additional risk factors, primary\/secondary prophylaxis and complications observed under normal clinical practice","volume":"22","year":"2008","journal-title":"Palliat. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1053\/clon.1999.9023","article-title":"The prevalence and associated variables of deep venous thrombosis in patients with advanced cancer","volume":"11","author":"Johnson","year":"1999","journal-title":"Clin. Oncol. (R Coll Radiol)."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e79","DOI":"10.1016\/S2352-3026(18)30215-1","article-title":"Prevalence, symptom burden and natural history of deep vein thrombosis in people with advanced cancer in specialist palliative care units (HIDDen): A prospective longitudinal observational study","volume":"6","author":"White","year":"2019","journal-title":"Lancet Haematol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"337","DOI":"10.2147\/PPA.S79373","article-title":"Patients\u2019 Experiences of LIving with CANcer-associated thrombosis: The PELICAN study","volume":"24","author":"Noble","year":"2015","journal-title":"Patient Prefer. Adherence"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1089\/rej.2013.1409","article-title":"Increased risk of chemotherapy-associated venous thromboembolism in elderly patients with cancer","volume":"16","author":"Vergati","year":"2013","journal-title":"Rejuvenation Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.6004\/jnccn.2018.0084","article-title":"NCCN Guidelines Insights: Cancer-Associated Venous Thromboembolic Disease, Version 2.2018","volume":"16","author":"Streiff","year":"2018","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1001\/archinte.164.9.963","article-title":"Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: Analysis of the MEDENOX Study","volume":"164","author":"Alikhan","year":"2004","journal-title":"Arch. Intern. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s11606-006-0019-x","article-title":"The impact of venous thromboembolism on risk of death or hemorrhage in older cancer patients","volume":"22","author":"Gross","year":"2007","journal-title":"J. Gen. Intern. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1160\/TH08-06-0390","article-title":"Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry","volume":"100","author":"Nieto","year":"2008","journal-title":"Thromb. Haemost."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e195S","DOI":"10.1378\/chest.11-2296","article-title":"Prevention of VTE in nonsurgical patients: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"141","author":"Kahn","year":"2012","journal-title":"Chest"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e000188","DOI":"10.1136\/esmoopen-2017-000188","article-title":"Antithrombotic therapy for prophylaxis and treatment of venous thromboembolism in patients with cancer: Review of the literature on current practice and emerging options","volume":"2","author":"Ay","year":"2017","journal-title":"ESMO Open"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"838","DOI":"10.3324\/haematol.2019.221424","article-title":"Updated meta-analysis on prevention of venous thromboembolism in ambulatory cancer patients","volume":"105","author":"Becattini","year":"2019","journal-title":"Haematologica"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1200\/JCO.19.01461","article-title":"Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update","volume":"38","author":"Key","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1186\/s13054-015-1003-9","article-title":"Venous thromboembolism in the ICU: Main characteristics, diagnosis and thromboprophylaxis","volume":"19","author":"Minet","year":"2015","journal-title":"Crit. Care"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","article-title":"Development and validation of a predictive model for chemotherapy-associated thrombosis","volume":"111","author":"Khorana","year":"2008","journal-title":"Blood"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1056\/NEJMoa1814630","article-title":"Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer","volume":"380","author":"Khorana","year":"2019","journal-title":"New Engl. J. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1111\/jth.14219","article-title":"Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: Guidance from the SSC of the ISTH","volume":"16","author":"Khorana","year":"2018","journal-title":"J. Thromb. Haemost."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1814468","article-title":"AVERT Investigators. Apixaban to prevent venous thromboembolism in patients with cancer","volume":"380","author":"Carrier","year":"2019","journal-title":"New. Engl. J. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1111\/jth.14564","article-title":"The use of direct oral anticoagulants for primary thromboprophylaxis in ambulatory cancer patients: Guidance from the SSC of the ISTH","volume":"17","author":"Wang","year":"2019","journal-title":"J. Thromb. Haemost."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"e566","DOI":"10.1016\/S1470-2045(19)30336-5","article-title":"for the International Initiative on Thrombosis and Cancer (ITAC) advisory panel. 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer","volume":"20","author":"Farge","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1111\/bjh.13556","article-title":"British Committee for Standards in H. guideline on aspects of cancer-related venous thrombosis","volume":"70","author":"Watson","year":"2015","journal-title":"Br. J. Haematol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/jth.13594","article-title":"Predictors of active cancer thromboembolic outcomes: Validation of the Khorana score among patients with lung cancer: Comment","volume":"15","author":"Noble","year":"2017","journal-title":"J. Thromb. Haemost."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.thromres.2017.06.021","article-title":"Incidence, outcome and risk stratification tools for venous thromboembolism in advanced pancreatic cancer\u2014A retrospective cohort study","volume":"157","author":"Kruger","year":"2017","journal-title":"Thromb. Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.thromres.2016.12.013","article-title":"The Khorana score for the prediction of venous thromboembolism in patients with pancreatic cancer","volume":"150","author":"Franke","year":"2017","journal-title":"Thromb. Res."},{"key":"ref_66","first-page":"2084","article-title":"Primary pharmacological prevention of thromboembolic events in ambulatory patients with advanced pancreatic cancer treated with chemotherapy?","volume":"138","author":"Pelzer","year":"2013","journal-title":"Dtsch. Med. Wochenschr."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ejim.2019.10.033","article-title":"Management of venous thromboembolism in cancer patients: Considerations about the clinical practice guideline update of the American society of clinical oncology","volume":"71","author":"Verso","year":"2020","journal-title":"Eur. J. Intern. Med."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Mulder, F.I., Bosch, F.T.M., and van Es, N. (2020). Primary Thromboprophylaxis in Ambulatory Cancer Patients: Where Do We Stand?. Cancers, 12.","DOI":"10.3390\/cancers12020367"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"e289","DOI":"10.1016\/S2352-3026(18)30063-2","article-title":"A clinical prediction model for cancer-associated venous thromboembolism: A development and validation study in two independent prospective cohorts","volume":"5","author":"Pabinger","year":"2018","journal-title":"Lancet Haematol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"e391","DOI":"10.1016\/S2352-3026(18)30111-X","article-title":"Artificial intelligence for cancer-associated thrombosis risk assessment","volume":"5","author":"Ferroni","year":"2018","journal-title":"Lancet Haematol."},{"key":"ref_71","unstructured":"National Institute for Health and Care Excellence (2020, May 03). Venous Thromboembolism in over 16s: Reducing the Risk of Hospital-Acquired Deep Vein Thrombosis or Pulmonary Embolism. Available online: https:\/\/www.nice.org.uk\/guidance\/ng89."},{"key":"ref_72","unstructured":"(2020, May 03). AIOM: Linee guida \u201cTromboembolismo venoso nei pazienti con tumori solidi\u201d. Available online: https:\/\/www.aiom.it\/linee-guida-aiom-tromboembolismo-venoso-nei-pazienti-con-tumori-solidi-2019\/."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1177\/0272989X16662654","article-title":"Risk Assessment for venous thromboembolism in chemotherapy-treated ambulatory cancer patients: A machine learning approach","volume":"37","author":"Ferroni","year":"2017","journal-title":"Med. Decis. Mak."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Riondino, S., Ferroni, P., Zanzotto, F.M., Roselli, M., and Guadagni, F. (2019). Predicting VTE in Cancer Patients: Candidate Biomarkers and Risk Assessment Models. Cancers, 11.","DOI":"10.3390\/cancers11010095"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/S0049-3848(09)70003-9","article-title":"RIETE Investigators. Predicting recurrences or major bleeding in women with cancer and venous thromboembolism. Findings from the RIETE Registry","volume":"123","author":"Luque","year":"2009","journal-title":"Thromb. Res."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D)","volume":"36","author":"Young","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","article-title":"Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer","volume":"382","author":"Agnelli","year":"2020","journal-title":"New Engl. J. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of cancer-associated venous thromboembolism","volume":"378","author":"Raskob","year":"2017","journal-title":"New Engl. J. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1111\/jth.14561","article-title":"Extended treatment with edoxaban in cancer patients with venous thromboembolism: A post-hoc analysis of the Hokusai-VTE Cancer study","volume":"17","author":"Carrier","year":"2019","journal-title":"J. Thromb. Haemost."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/ejh.13338","article-title":"Extending venous thromboembolism secondary prevention with apixaban in cancer patients: The EVE trial","volume":"104","author":"McBane","year":"2020","journal-title":"Eur. J. Haematol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.thromres.2019.11.007","article-title":"Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: Results from the Hokusai VTE Cancer study","volume":"185","author":"Mulder","year":"2020","journal-title":"Thromb. Res."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","article-title":"Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report","volume":"149","author":"Kearon","year":"2016","journal-title":"Chest"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1177\/0269216318815377","article-title":"Oral anticoagulation is preferable to injected but only if it is safe and effective: An interview study of patient and carer experience of oral and injected anticoagulant therapy for cancer-associated thrombosis in the select-d trial","volume":"33","author":"Hutchinson","year":"2019","journal-title":"Palliat. Med."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"S154","DOI":"10.1016\/S0049-3848(16)30115-3","article-title":"The treatment of cancer associated thrombosis: Does one size fit all? Who should get LMWH\/warfarin\/DOACs?","volume":"140","author":"Noble","year":"2016","journal-title":"Thromb. Res."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/S0140-6736(59)91464-3","article-title":"Prevention of venous thrombosis and pulmonary embolism in injured patients. A trial of anticoagulant prophylaxis with phenindione in middle-aged and elderly patients with fractured necks of the femur","volume":"2","author":"Sevitt","year":"1959","journal-title":"Lancet"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1538-7836.2009.03384.x","article-title":"Prevention of venous thromboembolism: A key patient safety priority","volume":"7","author":"Geerts","year":"2009","journal-title":"J. Thromb. Haemost."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1200\/JOP.2012.000698","article-title":"Inpatient hospitalization of oncology patients: Are we missing an opportunity for end-of-life care?","volume":"9","author":"Rocque","year":"2013","journal-title":"J. Oncol. Pract."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.thromres.2018.12.028","article-title":"Thromboembolic disease in palliative and end-of-life care: A narrative review","volume":"175","author":"Tanuseputro","year":"2019","journal-title":"Thromb. Res."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1177\/0269216319830860","article-title":"Thromboprophylaxis for inpatients with advanced cancer in palliative care settings: A systematic review and narrative synthesis","volume":"33","author":"Cai","year":"2019","journal-title":"Palliat. Med."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Noble, S., Banerjee, S., and Pease, N.J. (2019). Management of venous thromboembolism in far-advanced cancer: Current practice. BMJ Support. Palliat. Care.","DOI":"10.1136\/bmjspcare-2019-001804"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/jth.13606","article-title":"Bleeding risk of terminally ill patients hospitalized in palliative care units: The RHESO study","volume":"15","author":"Tardy","year":"2017","journal-title":"J. Thromb. Haemost."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1136\/pgmj.2007.061622","article-title":"The challenges of managing cancer related venous thromboembolism in the palliative care setting","volume":"83","author":"Noble","year":"2007","journal-title":"Postgrad. Med. J."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jpainsymman.2013.08.016","article-title":"Primary thromboprophylaxis in hospices: The association between risk of venous thromboembolism and development of symptoms","volume":"48","author":"Johnson","year":"2014","journal-title":"J. Pain Symptom Manag."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1089\/jpm.2009.0373","article-title":"Administrative outcomes five years after opening an acute palliative care unit at a comprehensive cancer center","volume":"13","author":"Bryson","year":"2010","journal-title":"J. Palliat. Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1089\/jpm.2009.0166","article-title":"Discharge outcomes and survival of patients with advanced cancer admitted to an acute palliative care unit at a comprehensive cancer center","volume":"13","author":"Hui","year":"2010","journal-title":"J. Palliat. Med."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1007\/s00520-011-1330-6","article-title":"Thromboprophylaxis in patients receiving inpatient palliative care: A survey of present practice in Austria","volume":"20","author":"Gartner","year":"2012","journal-title":"Support. Care Cancer."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1177\/0269216315598671","article-title":"Coverage and development of specialist palliative care services across the World Health Organization European Region (2005-2012): Results from a European Association for Palliative Care Task Force survey of 53 Countries","volume":"30","author":"Centeno","year":"2016","journal-title":"Palliat. Med."},{"key":"ref_98","unstructured":"US Food and Drug Administration (2020, February 10). Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Iclaims, Available online: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-reported-outcome-measures-use-medical-product-development-support-labeling-claims."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3322\/caac.21150","article-title":"Electronic patient-reported outcome systems in oncology clinical practice","volume":"62","author":"Bennett","year":"2012","journal-title":"CA Cancer J. Clin."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"e118","DOI":"10.2196\/jmir.2214","article-title":"Electronic symptom reporting between patient and provider for improved health care service quality: A systematic review of randomized controlled trials. part 1: State of the art","volume":"14","author":"Johansen","year":"2012","journal-title":"J. Med. Internet Res."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s11136-008-9436-0","article-title":"Logistics of collecting patient-reported outcomes (PROs) in clinical practice: An overview and practical examples","volume":"18","author":"Rose","year":"2009","journal-title":"Qual. Life Res."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1007\/s40264-016-0437-6","article-title":"Innovative Digital Tools and Surveillance Systems for the Timely Detection of Adverse Events at the Point of Care: A Proof of Concept Study","volume":"39","author":"Hoppe","year":"2016","journal-title":"Drug Saf."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"104","DOI":"10.21037\/apm.2017.07.05","article-title":"PROutine: A feasibility study assessing surveillance of electronic patient reported outcomes and adherence via smartphone app in advanced cancer","volume":"8","author":"Benze","year":"2019","journal-title":"Ann. Palliat. Med."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1186\/s12885-018-5154-3","article-title":"Early venous thromboembolism at the beginning of palliative chemotherapy is a poor prognostic factor in patients with metastatic pancreatic cancer: A retrospective study","volume":"18","author":"Kim","year":"2018","journal-title":"BMC Cancer"},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Hannon, B., Taback, N., Zimmermann, C., Granton, J., and Krzyzanowska, M. (2019). Medical oncologists\u2019 and palliative care physicians\u2019 opinions towards thromboprophylaxis for inpatients with advanced cancer: A cross-sectional study. BMJ Support. Palliat. Care.","DOI":"10.1136\/bmjspcare-2019-001861"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1177\/0269216308096723","article-title":"Factors influencing hospice thromboprophylaxis policy: A qualitative study","volume":"22","author":"Noble","year":"2008","journal-title":"Palliat. Med."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/5\/1167\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T14:09:59Z","timestamp":1760364599000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/5\/1167"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,6]]},"references-count":106,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,5]]}},"alternative-id":["cancers12051167"],"URL":"https:\/\/doi.org\/10.3390\/cancers12051167","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,6]]}}}